Guangzhou and Shenzhen will split the work of building China’s most quantitatively ambitious provincial brain-computer interface industry under a five-year Action Plan released on 24 June 2026. Shenzhen, the southern tech megacity that hosts Huawei, Tencent and BYD, anchors the invasive-device, neural-signal decoding, and chip-and-system integration pillar. Guangzhou, the Pearl River Delta capital, anchors the full-chain ecosystem and clinical translation pillar through a new “Guangzhou Brain Valley” campus spanning its Haizhu and Tianhe districts. By 2030, the two cities are together committed to a 10 billion yuan (approximately $1.4 billion) core BCI industry, 100 new science-and-technology enterprises in the category, 200 dedicated BCI hospital wards across Guangdong, and more than 500,000 cumulative patient service interactions. The two-city division of labour is named in the plan as “Dual-Core” (双核).

The plan was issued by the Office of the Science and Technology Commission of the Chinese Communist Party’s Guangdong Provincial Committee, per 36Kr’s English-language reporting and the underlying Chinese-language coverage by Yang Huan in the “Urban Evolution Theory” WeChat publication. It operationalises at provincial level the seven-ministry Implementation Opinions on Promoting the Innovative Development of the Brain-Computer Interface Industry (工信部联科〔2025〕164号) that Beijing issued on 23 July 2025. The release fell one day after Vice Premier Liu Guozhong’s 23 June 2026 inspection of the Brain-Computer Interface Research Institute at Nanjing University, during a 22-23 June Jiangsu tour.

What the Action Plan actually targets

The 2030 targets in the Guangdong plan, as reported by 36Kr and corroborated by Sci-Tech Daily (stdaily.com), are organised in a five-actions-sixteen-measures structure. The 10 billion yuan target applies to the core BCI industry. The plan also references a 100 billion yuan radiated upstream and downstream scale, which is a broader supply-chain and service-economy framing rather than the core device industry alone. The 100 new sci-tech enterprises target is for net new additions, not cumulative registrations, and uses the Chinese policy term 科技型企业 (science-and-technology-type enterprises), which carries specific provincial classification criteria.

Additional 2030 targets named in the plan: ten or more commercial non-invasive BCI products, multiple invasive products advanced into National Medical Products Administration clinical translation pathways, 100 benchmark BCI application scenarios, 200 BCI hospital wards established province-wide, and more than 500,000 cumulative service person-times for patients and end users. The plan also references a 2027 interim milestone of clinical translation across five or more brain diseases and ten or more backbone enterprises. The plan flags “a batch of” unicorn enterprises (those valued above $1 billion in standard usage) as a 2030 ambition without specifying a target unicorn count.

The “Dual-Core” Guangzhou and Shenzhen division

The “Dual-Core” structure assigns differentiated roles to the two anchor cities. Shenzhen is positioned as the anchor for invasive BCI devices, neural-signal decoding, and system integration. Guangzhou is positioned as the anchor for the full-chain BCI ecosystem and is identified by the plan as the location of a “Guangzhou Brain Valley” spanning the Haizhu and Tianhe districts. The geographic separation produces a complementary rather than competing structure across the two cities, similar in concept to the division of labour visible in other Chinese sci-tech provinces where one city anchors device manufacturing and the other anchors integrated commercial deployment.

Pazhou Laboratory (琶洲实验室) in Guangzhou’s Haizhu District is the principal Guangdong research institution surfaced in available coverage of the plan’s local-assets discussion. The Li Yuanqing team, with Li Yuanqing concurrently serving as Executive Deputy Director of Pazhou Laboratory and Professor at South China University of Technology, partnered with Southern Medical University Zhujiang Hospital to establish South China’s first dedicated BCI clinical ward in June 2025, which now operates as the named clinical translation anchor on the Guangdong side. The plan does not name commercial Chinese BCI companies headquartered outside Guangdong (Neuracle in Shanghai, BrainCo in Hangzhou, StairMed in Shanghai, NeuCyber in Beijing) as Guangdong assets, consistent with the geographic accuracy of the plan’s own provincial scope.

How this operationalises the July 2025 national framework

The Guangdong Action Plan is the most fully quantified provincial implementation to date of the central national framework that Beijing established in mid-2025. On 23 July 2025, seven central agencies (the Ministry of Industry and Information Technology as lead, plus the National Development and Reform Commission, the Ministry of Education, the National Health Commission, the State-owned Assets Supervision and Administration Commission, the Chinese Academy of Sciences, and the National Medical Products Administration) jointly issued the Implementation Opinions on Promoting the Innovative Development of the Brain-Computer Interface Industry (工信部联科〔2025〕164号), publicly released through gov.cn on 7 August 2025. That document set 2027 milestones for breakthroughs in key BCI technologies and the formation of two to three industry development clusters, and 2030 milestones for two to three globally influential leading BCI enterprises plus a cohort of specialised, refined, distinctive, and innovative (专精特新) small and medium enterprises. The Opinions are structured around five major tasks, three flagship engineering programs, and seventeen specific measures, with funding routed through the National Manufacturing Transformation and Upgrading Fund and the National SME Development Fund.

The Guangdong 24 June 2026 plan is the most fully quantified provincial Action Plan to date translating the seven-ministry national framework into a provincial blueprint, with specific yuan-denominated industrial-output targets, a named geographic structure (“Dual-Core” Guangzhou and Shenzhen), a 200-ward clinical infrastructure commitment, and a 100-new-enterprise net additions target. Shanghai pre-empted the post-Opinions provincial cascade with its own dedicated BCI Future Industry Cultivation Action Plan 2025-2030 (沪科〔2025〕5号) issued on 10 January 2025, which preceded the national Opinions by six months. The first post-Opinions provincial Action Plan was Jiangsu’s, jointly issued by nine departments on 10 March 2026. Guangdong is the second post-Opinions provincial Action Plan and is more aggressive in quantitative ambition than the Jiangsu plan. The pattern visible across Shanghai (Jan 2025) to national Opinions (Jul 2025) to Jiangsu (Mar 2026) to Guangdong (Jun 2026) is provincial cascade orchestrated around a specific central directive, with the July 2025 seven-ministry national Opinions as the institutional headwater for the post-July 2025 wave.

The cascade matters because it identifies the layer at which the next material Chinese BCI policy moves will be issued. The next national-level documents to watch are ministry-level implementing regulations from the named seven agencies, particularly NMPA clinical-pathway guidance and NHSA pricing-pathway integration. The next provincial-level documents to watch are Action Plans from Beijing, Sichuan, Anhui, Hubei, and Shandong following the Jiangsu and Guangdong template. The institutional clock that started with the July 2025 national Opinions is now running at provincial implementation cadence, and Guangdong is its most quantitatively committed expression to date.

How this fits the China BCI institutional architecture

Guangdong is the fifth Chinese province or municipal jurisdiction to anchor a publicly named BCI institutional vehicle in 2026, following Tianjin (the BCI Industrial Cluster inaugurated 29 May 2026 with 100 million yuan annual funding), Shanghai (where Neuracle Technology’s Shanghai entity filed the 11 June 2026 STAR Market IPO prospectus), Jiangsu (where Nanjing University’s Brain-Computer Interface Research Institute received the Liu Guozhong inspection on 23 June 2026), and Zhejiang (anchored by BrainCo’s January 2026 confidential Hong Kong Stock Exchange filing). The verified institutional cadence is now five geographically distinct anchors in seven months. Jiangsu had separately issued its provincial BCI Industry Innovation Development Action Plan on 10 March 2026, jointly by nine departments, as the first publicly named provincial Action Plan to follow the July 2025 national Opinions.

The institutional pattern visible from Tianjin through Guangdong is distributed across multiple metropolitan research bases rather than concentrated in a single national centre. Each anchor produces a different operating modality. Tianjin operates as a city-funded industrial cluster with a research lab and clinical translation hospitals on a 100 million yuan annual budget. Shanghai operates as a commercial-capital-markets anchor with Neuracle’s STAR Market filing as the visible milestone. Hangzhou operates as a Hong Kong-listing-track anchor through BrainCo. Jiangsu operates as a research-and-policy anchor with the NJU institute and a March 2026 provincial Action Plan. Guangdong now operates as a twin-city ecosystem anchor under the Dual-Core framework, with explicit 2030 industrial-output and enterprise-count targets that are larger in scale than any single previous provincial commitment.

The Guangdong Action Plan is issued not by the Guangdong Provincial Government or by the Provincial Development and Reform Commission, but by the Office of the Science and Technology Commission of the Communist Party’s Guangdong Provincial Committee. The Party-level rather than government-level routing is itself a substantive policy signal. BCI is being treated as a strategic technology priority requiring Party-direction coordination, parallel to how semiconductors, AI, and biotech have been routed through Party-level coordination committees rather than through standard government industrial-policy channels.

What to watch

The first signal to watch is whether Pazhou Laboratory in Guangzhou and the Shenzhen-anchored invasive device pillar produce dated implementation milestones within the next two quarters. Provincial Action Plans of this type typically convert into ministerial-level implementing language and into city-level matching funds over a four-to-six-month window. The Guangzhou Brain Valley physical-infrastructure build-out and the Shenzhen invasive-device clinical-translation pipeline are the two visible operational layers to track.

The second signal is whether the Southern Medical University Zhujiang Hospital BCI ward expands its first-in-South-China clinical translation pattern into the broader 200 BCI wards target by 2030. The 200-ward target is a large clinical infrastructure commitment relative to the existing footprint and implies clinical-translation activity across multiple major Guangdong tertiary hospitals.

The third signal is whether other major Chinese provinces or sci-tech-driven municipalities (Beijing, Sichuan, Anhui, Hubei, Shandong) issue parallel BCI provincial Action Plans within the next six months. A Guangdong Action Plan following Jiangsu’s March 2026 plan establishes a two-province pattern. A third or fourth provincial Action Plan in the same calendar would convert the pattern into a national one, which would in turn imply that the central-government direction articulated by Liu Guozhong is now operationalising at provincial implementation level across the Chinese state apparatus.

Sources

• Striving for a 10-Billion-Level Industry, How Does Guangdong’s “Dual-Core” Labor Division Work (36Kr English, Yang Huan, 26 June 2026)
• Sci-Tech Daily corroborating coverage of the Guangdong BCI Action Plan (stdaily.com)
• Implementation Opinions on Promoting the Innovative Development of the BCI Industry, 工信部联科〔2025〕164号 (gov.cn, 7 August 2025)
• Shanghai BCI Future Industry Cultivation Action Plan 2025-2030, 沪科〔2025〕5号 (10 January 2025)
• Jiangsu Provincial BCI Industry Innovation Development Action Plan, jointly issued by nine departments (10 March 2026)
• CSET Georgetown English translation of the Seven-Ministry BCI Implementation Opinions
• Pazhou Laboratory (琶洲实验室) institutional profile
• Southern Medical University Zhujiang Hospital
• Inside BCI: Liu Guozhong NJU visit, 25 June 2026 · Tianjin BCI Industrial Cluster, 17 June 2026 · Neuracle STAR Market IPO acceptance, 22 June 2026 · Asia-Pacific synthesis, 21 June 2026